Retrospective, External Comparator Study of Lazertinib as the 2nd-Line Treatment in Patients With EGFR Mutation+ NSCLC

Clinical trial NCT05862194 · COMPLETED

Trial details

NCT number: NCT05862194
Sponsor: Yuhan Corporation
Status: COMPLETED
Study type: OBSERVATIONAL

Non-small Cell Lung Cancer

Start date: 2015-06-01
Primary completion: 2022-04-30
Enrollment: 534

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.